<SEC-DOCUMENT>0001213900-20-043965-index.html : 20201222 <SEC-HEADER>0001213900-20-043965.hdr.sgml : 20201222 <ACCEPTANCE-DATETIME>20201222091544 ACCESSION NUMBER: 0001213900-20-043965 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 4 CONFORMED PERIOD OF REPORT: 20201222 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20201222 DATE AS OF CHANGE: 20201222 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SOLIGENIX, INC. CENTRAL INDEX KEY: 0000812796 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 411505029 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-14778 FILM NUMBER: 201406294 BUSINESS ADDRESS: STREET 1: 29 EMMONS DRIVE STREET 2: SUITE B-10 CITY: PRINCETON STATE: NJ ZIP: 08540 BUSINESS PHONE: 609-538-8200 MAIL ADDRESS: STREET 1: 29 EMMONS DRIVE STREET 2: SUITE B-10 CITY: PRINCETON STATE: NJ ZIP: 08540 FORMER COMPANY: FORMER CONFORMED NAME: DOR BIOPHARMA INC DATE OF NAME CHANGE: 20020329 FORMER COMPANY: FORMER CONFORMED NAME: ENDOREX CORP DATE OF NAME CHANGE: 19960916 FORMER COMPANY: FORMER CONFORMED NAME: IMMUNOTHERAPEUTICS INC DATE OF NAME CHANGE: 19920703 </SEC-HEADER> <DOCUMENT> <TYPE>8-K <SEQUENCE>1 <FILENAME>ea132049-8k_soligenixinc.htm <DESCRIPTION>CURRENT REPORT <TEXT> Document 1 - file: ea132049-8k_soligenixinc.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-99.1 <SEQUENCE>2 <FILENAME>ea132049ex99-1_soligenixinc.htm <DESCRIPTION>PRESS RELEASE OF SOLIGENIX, INC. DATED DECEMBER 22, 2020 <TEXT> Document 2 - file: ea132049ex99-1_soligenixinc.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-99.2 <SEQUENCE>3 <FILENAME>ea132049ex99-2_soligenixinc.htm <DESCRIPTION>SOLIGENIX, INC. CONFERENCE CALL SCRIPT DATED DECEMBER 22, 2020 <TEXT> Document 3 - file: ea132049ex99-2_soligenixinc.htm
</DOCUMENT> <DOCUMENT> <TYPE>GRAPHIC <SEQUENCE>4 <FILENAME>ex99-1_001.jpg <DESCRIPTION>GRAPHIC <TEXT> Document 4 - file: ex99-1_001.jpg
</DOCUMENT> </SEC-DOCUMENT>